Q2 2024 Earnings Estimate for GSK plc Issued By Zacks Research (NYSE:GSK)

GSK plc (NYSE:GSK) – Research analysts at Zacks Research dropped their Q2 2024 EPS estimates for GSK in a report issued on Wednesday, May 22nd. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings of $1.00 per share for the quarter, down from their previous estimate of $1.10. The consensus estimate for GSK’s current full-year earnings is $4.12 per share. Zacks Research also issued estimates for GSK’s Q4 2024 earnings at $0.83 EPS and Q2 2025 earnings at $0.99 EPS.

A number of other research analysts have also recently commented on GSK. Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

GSK Stock Performance

Shares of NYSE GSK opened at $45.12 on Friday. The stock’s 50-day moving average is $42.53 and its 200 day moving average is $40.16. The stock has a market cap of $93.51 billion, a price-to-earnings ratio of 16.35, a P/E/G ratio of 1.36 and a beta of 0.65. GSK has a 1-year low of $33.33 and a 1-year high of $45.92. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.15. GSK had a return on equity of 51.54% and a net margin of 14.62%. The firm had revenue of $9.34 billion during the quarter, compared to analyst estimates of $8.98 billion.

Hedge Funds Weigh In On GSK

Large investors have recently bought and sold shares of the stock. 1832 Asset Management L.P. boosted its stake in shares of GSK by 9.1% during the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock valued at $132,000 after purchasing an additional 257 shares during the period. Personal CFO Solutions LLC increased its stake in shares of GSK by 2.7% in the fourth quarter. Personal CFO Solutions LLC now owns 10,087 shares of the pharmaceutical company’s stock worth $374,000 after buying an additional 263 shares during the period. J.W. Cole Advisors Inc. raised its holdings in GSK by 4.7% during the 1st quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock valued at $261,000 after buying an additional 271 shares during the last quarter. Chapin Davis Inc. boosted its position in GSK by 2.2% during the 1st quarter. Chapin Davis Inc. now owns 14,231 shares of the pharmaceutical company’s stock valued at $610,000 after buying an additional 300 shares during the period. Finally, Dorsey & Whitney Trust CO LLC boosted its position in GSK by 2.9% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 10,986 shares of the pharmaceutical company’s stock valued at $407,000 after buying an additional 306 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be issued a dividend of $0.3762 per share. The ex-dividend date is Thursday, May 16th. This is a boost from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 annualized dividend and a yield of 3.34%. GSK’s dividend payout ratio is currently 53.26%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.